Table 2.
Baseline characteristics of interventions included in the analysis.
Interventions n = 328 | Percentage % | ||
---|---|---|---|
Mastectomy | Prophylactic | 61 | 18.6% |
Therapeutic | 267 | 81.4% | |
Mastectomy | NSM | 229 | 69.8% |
NSM-modified “T-inverted” | 17 | 5.2% | |
SRM - Nipple Sparing | 10 | 3.0% | |
SRM- No Nipple Sparing | 7 | 2.1% | |
SSM | 65 | 19.8% | |
Previous Surgery | 1 = Wide Excision Unilateral | 34 | 10.4% |
2 = Wide Excision Contralateral | 5 | 1.5% | |
4 = QUART Unilateral | 34 | 10.4% | |
5 = QUART Contralateral | 7 | 2.1% | |
6 = Breast Augmentation | 7 | 2.1% | |
7 = Contralateral Mastectomy | 22 | 6.7% | |
8 = None | 219 | 66.8% | |
Axilla | SNB Final | 102 | 31.1% |
SNB Intraoperative Negative | 77 | 23.5% | |
SNB + Axillary Dissection | 22 | 6.7% | |
SNB + Axillary Dissection Delayed | 15 | 4.6% | |
Axillary Dissection | 37 | 11.3% | |
No | 75 | 22.9% | |
Cutting | Linear | 59 | 18.0% |
Periareolar | 21 | 6.4% | |
S in External Quadrants | 200 | 61.0% | |
Inframammary Fold | 10 | 3.0% | |
Inverted T | 36 | 11.0% | |
Vertical | 2 | 0.6% | |
Radiotherapy | No adjuvant | 278 | 85.0% |
Yes adjuvant | 49 | 15.0% | |
Chemotherapy | Adjuvant | 93 | 28.4% |
Neo-adjuvant | 30 | 9.1% | |
No | 205 | 62.5% | |
Hormone Therapy | No | 138 | 42.2 |
Yes | 189 | 57.8 | |
Trastuzumab | No | 277 | 84.7 |
Yes | 50 | 15.3 | |
Device | Prosthesis (DTI) | 192 | 58.5 |
Expander (TE) | 136 | 41.5 | |
pT | T0 | 79 | 24.1 |
Tis | 44 | 13.4 | |
T1 | 156 | 47.6 | |
T2 | 47 | 14.3 | |
T3 | 2 | 0.6 | |
pN | N0-X | 251 | 76.4 |
N1 | 52 | 15.9 | |
N2 | 13 | 4.0 | |
N3 | 12 | 3.7 | |
ER | – | 30 | 9.1 |
+ | 214 | 65.2 | |
Not performed | 84 | 25.6 | |
PgR | – | 52 | 15.9 |
+ | 192 | 58.5 | |
Not performed | 84 | 25.6 | |
Ki67 | <20% | 79 | 24.1 |
>20% | 130 | 36.9 | |
Not performed | 119 | 36.3 | |
Her 2 | Amplified | 51 | 15.5 |
Lymph-nodes invasion | Absent | 145 | 44.2 |
Present | 56 | 17.1 | |
Missing | 127 | 38.7 |